Alaunos Therapeutics Inc TCRT:NASDAQ

Last Price$0.50NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$0.50 (20)
Ask (Size)$0.52 (29)
Day Low / HighN/A - N/A
Volume1.0 M

View Biotechnology IndustryPeer Comparison as of 05/20/2022


Alaunos Therapeutics Inc ( NASDAQ )

Price: $0.50
Change: +0.02 (3.34%)
Volume: 1.0 M
4:00PM ET 5/20/2022

Precision BioSciences Inc ( NASDAQ )

Price: $1.71
Change: -0.02 (1.16%)
Volume: 700.5 K
4:00PM ET 5/20/2022

CytomX Therapeutics Inc ( NASDAQ )

Price: $1.62
Change: -0.07 (4.14%)
Volume: 648.4 K
4:00PM ET 5/20/2022

NextCure Inc ( NASDAQ )

Price: $3.79
Change: +0.15 (4.12%)
Volume: 68.5 K
4:00PM ET 5/20/2022

Paratek Pharmaceuticals Inc ( NASDAQ )

Price: $1.93
Change: +0.03 (1.58%)
Volume: 270.4 K
4:00PM ET 5/20/2022

Read more news Recent News

--Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight
7:22AM ET 5/04/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Alaunos Therapeutics Doses First Patient in Phase 1/2 Trial of TCR-T Cell Therapy in Solid Tumors
10:49AM ET 5/02/2022 MT Newswires

Alaunos Therapeutics (TCRT) said Monday it has dosed the first patient in a phase 1/2 trial of TCR-T cell therapy for patients with solid tumors. The...

Sector Update: Health Care Stocks Recoup Portion of Prior Losses
3:52PM ET 9/28/2021 MT Newswires

Health care stocks were ending well above their intra-day lows this afternoon, with the NYSE Health Care Index falling 1.1% in late trade while the SPDR...

Sector Update: Health Care Stocks Losing More Ground as Selloff Accelerates
1:15PM ET 9/28/2021 MT Newswires

Health care stocks were mostly lower this afternoon, with the NYSE Health Care Index falling 1.8%, while the SPDR Health Care Select Sector ETF (XLV) was...

Company Profile

Business DescriptionAlaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX. View company web site for more details
Address8030 El Rio Street
Houston, Texas 77054
Number of Employees48
Recent SEC Filing05/16/20228-K
Chief Executive Officer & DirectorKevin S. Boyle
Executive Vice President-OperationsEleanor M. de Groot
Chief Financial OfficerTimothy M. Cunningham
Vice President-Research & DevelopmentDrew Deniger

Company Highlights

Price Open$0.48
Previous Close$0.48
52 Week Range$0.41 - 3.73
Market Capitalization$107.5 M
Shares Outstanding216.0 M
SectorHealth Technology
Next Earnings Announcement08/12/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.35
Beta vs. S&P 500N/A
Revenue$146.0 K
Net Profit Margin-19,786.68%
Return on Equity-98.23%

Analyst Ratings as of 05/03/2022

Consensus RecommendationConsensus Icon
Powered by Factset